Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programmes for the potential treatment of neuromuscular and ocular diseases, among others. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. Show more
Location: One Design Center Place, Boston, MA, 02210, United States | Website: https://www.entradatx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
223.3M
52 Wk Range
$4.93 - $21.79
Previous Close
$6.18
Open
$6.14
Volume
126,034
Day Range
$5.67 - $6.24
Enterprise Value
-74.09M
Cash
354M
Avg Qtr Burn
-30.97M
Insider Ownership
12.30%
Institutional Own.
78.07%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|